Cafepharma Today

May 21 2025 - Medtronic plans to separate its diabetes business into a new company
Medtronic plans to separate its diabetes business into a new company
Moderna shares down after pulling Covid-flu combo vaccine application
Roche's Genentech sticks with Orionis in 2nd molecular glue deal worth $2B
RFK Jr. takes fire in Senate hearing on research cuts
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Can Horizon Pharma (HZNP) Run Higher on Strong Earnings Estimate Revisions?
Yahoo/Zacks.com
Tuesday, February 25, 2014 - 7:23am
tags:
Horizon Pharma, earnings
5 Pharmas Spending the Most to Develop Drugs: Merck, AstraZeneca, Roche, Bristol, and Lilly
Motley Fool
Tuesday, February 25, 2014 - 7:22am
tags:
Merck, AstraZeneca, Roche, Bristol-Myers Squibb, Eli Lilly, R&D, drug development
VIVUS' Q4 Loss Shrinks 70% as Licensing Revenue Soars
Motley Fool
Monday, February 24, 2014 - 5:39pm
tags:
Vivus, earnings
Cheaper Obesity Drugs Available (for Half of Some Americans)
Daily Finance
Monday, February 24, 2014 - 5:25pm
tags:
obesity, Arena Pharmaceuticals, Eisai, Vivus, Orexigen, Belviq, Qsymia, Contrave
FDA Denies 3 Petitions Seeking NCE Exclusivity for Combo Drugs, But Proposes to Reinterpret the Law for New NDAs
FDA Law Blog
Monday, February 24, 2014 - 5:18pm
tags:
FDA, exclusivity
Syneron names new CEO, beats The Street and buys New Star Lasers
Mass Device
Monday, February 24, 2014 - 5:15pm
tags:
Syneron, earnings, M&A, New Star Lasers, devices
With Teva's Symbicort copy nearing EU launch, AstraZeneca preps for battle
Fierce Pharma
Monday, February 24, 2014 - 5:11pm
tags:
Symbicort, generics, Europe, AstraZeneca, Teva Pharmaceuticals
Will the generics M&A surge put Teva on the takeover table?
Fierce Pharma
Monday, February 24, 2014 - 5:08pm
tags:
generics, M&A, Teva Pharmaceuticals
Biotech: Too Big for Its Britches?
Barron's
Monday, February 24, 2014 - 5:05pm
tags:
biotech, Celgene, Gilead Sciences, Biogen Idec, Amgen, Regeneron
Here's Why You Should Look Beyond NICE's Pushback on Tecfidera
Motley Fool
Monday, February 24, 2014 - 5:01pm
tags:
Tecfidera, NICE, MS, multiple sclerosis, Biogen Idec
Jazz Pharma To Guide 2014 With New Drugs On Board
Investors.com
Monday, February 24, 2014 - 4:59pm
tags:
Jazz Pharmaceuticals, ADX-N05, earnings
Isis Pharma Soars on Positive Data
Yahoo/Zacks.com
Monday, February 24, 2014 - 4:50pm
tags:
Isis Pharmaceuticals, ISIS-SMNRx, spinal muscular atrophy
Celsion Announces FDA Clearance of the OPTIMA Study - A Pivotal Phase III Trial of ThermoDox in Primary Liver Cancer
Yahoo
Monday, February 24, 2014 - 11:16am
tags:
FDA, Celsion, liver cancer, ThermoDox
The 10 Most Heavily Shorted Bio-Pharma Stocks
TheStreet.com
Monday, February 24, 2014 - 11:15am
tags:
Spectrum Pharmaceuticals, Dendreon, Achillion, Ziopharm, Intrexon, Arena Pharmaceuticals, Idenix, Synta Pharmaceuticals, Sarepta Therapeutics, Myriad Genetics
ImmunoCellular: Is Approval Enough?
Seeking Alpha
Monday, February 24, 2014 - 11:12am
tags:
ImmunoCellular Therapeutics, ICT-107, DCVax®-L, Northwest Biotherapeutics, glioblastoma multiforme
2 Cell Therapy Companies That Could Thrive With Cardiovascular Disease Treatments
Seeking Alpha
Monday, February 24, 2014 - 11:11am
tags:
stem cells, cardiovascular disease, Athersys, NeoStem, AMR-001, MultiStem
3 Under-the-Radar Biotech Stocks You Need to Watch in 2014
Motley Fool
Monday, February 24, 2014 - 10:10am
tags:
Nektar, Omeros, Spectrum Pharmaceuticals
Bayer Set to Acquire Algeta in First Quarter
Marketwatch
Monday, February 24, 2014 - 10:07am
tags:
Bayer, Algeta, M&A
Ardelyx licenses NaP2b phosphate inhibitor program to Sanofi
Yahoo/Fly on the Wall
Monday, February 24, 2014 - 9:57am
tags:
Sanofi, Ardelyx, NaP2b phosphate inhibitor
Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for All-Oral Daclatasvir Dual Investigational Regimen for Chronic Hepatitis C
Yahoo
Monday, February 24, 2014 - 9:55am
tags:
daclatasvir, breakthrough therapies, FDA, Bristol-Myers Squibb, hepatitis C

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline
Lose Your Crystalline Form and Go Amorphous
In the Pipeline
Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.